ENTRADA THERAPEUTICS, INC. Shareholders' Equity
ENTRADA THERAPEUTICS, INC. (TRDA) had Shareholders' Equity of $233.41 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-05
- 2026-06-30: Stockholders' Equity Attributable to Parent $233.41M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $270.85M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $306.13M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $340.72M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $233.41M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $270.85M 10-Q · filed 2026-08-05 |
| 2025-12-31 | $306.13M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $340.72M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $379.50M 10-Q · filed 2026-08-05 |
| 2025-03-31 | $417.26M 10-Q · filed 2026-08-05 |
| 2024-12-31 | $428.68M 10-Q · filed 2026-08-05 |
| 2024-09-30 | $422.45M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $429.93M 10-Q · filed 2025-11-06 |
| 2024-03-31 | $269.37M 10-Q · filed 2025-11-06 |
| 2023-12-31 | $242.36M 10-K · filed 2026-02-26 |
| 2023-09-30 | $246.66M 10-Q · filed 2024-11-05 |
| 2023-06-30 | $206.91M 10-Q · filed 2024-11-05 |
| 2023-03-31 | $229.61M 10-Q · filed 2024-11-05 |
| 2022-12-31 | $212.55M 10-K · filed 2025-02-27 |
| 2022-09-30 | $233.22M 10-Q · filed 2023-11-07 |
| 2022-06-30 | $256.04M 10-Q · filed 2023-11-07 |
| 2022-03-31 | $277.39M 10-Q · filed 2023-11-07 |
| 2021-12-31 | $298.72M 10-K · filed 2024-03-13 |
| 2021-09-30 | -$72.59M 10-Q · filed 2022-11-07 |
| 2021-06-30 | -$59.01M 10-Q · filed 2022-11-07 |
| 2021-03-31 | -$49.67M 10-Q · filed 2022-11-07 |
| 2020-12-31 | -$41.49M 10-K · filed 2023-03-06 |
| 2020-09-30 | -$33.05M 10-Q · filed 2021-12-09 |
| 2020-06-30 | -$26.14M 10-Q · filed 2021-12-09 |
| 2020-03-31 | -$20.12M 10-Q · filed 2021-12-09 |
| 2019-12-31 | -$15.52M 10-K · filed 2022-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |